YAP/TEAD Cancer Research Results

YAP/TEAD, YAP/TEAD activity: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
YAP (Yes-associated protein) and TEAD (TEA domain transcription factors) are key components of the Hippo signaling pathway, which plays a crucial role in regulating cell growth, proliferation, and apoptosis.
Activation of YAP: In normal conditions, the Hippo pathway inhibits YAP activity, preventing excessive cell growth. However, when the Hippo pathway is inactivated (due to mutations or other factors), YAP becomes activated. This leads to increased cell proliferation and survival, contributing to tumorigenesis.
TEAD as a Transcription Factor: YAP interacts with TEAD proteins to drive the expression of target genes that promote cell growth and inhibit apoptosis. This YAP/TEAD complex is often found to be overactive in several types of cancer, including liver, breast, and lung cancers.
Scientific Papers found: Click to Expand⟱
7907- Api,  IVT,    Anticancer Potential of Apigenin and Isovitexin with Focus on Oncogenic Metabolism in Cancer Stem Cells
- Review, Var, NA
ChemoSen↑, CSCs↓, Wnt↓, β-catenin/ZEB1↓, PI3K↓, MMP↓, TumMeta↓, MAPK↓, VEGF↓, MMP9↓, TGF-β↓, Inflam↓, COX2/PTGS2↓, IL6↓, NF-kB↓, TumCCA↑, P53↑, cycD1/CCND1↓, BAX↑, Casp↓, Bcl-2↓, CD133↓, Nanog↓, SOX2↓, Akt↓, TumCP↓, TumCMig↓, YAP/TEAD↓, CCN2/CTGF↓, CCN1/CYR61↓, SIRT3↓, SIRT6↓, PCNA↓, DNMT1↓, miR-34a↑,
5380- ART/DHA,    Artemisinin and Its Derivatives as Potential Anticancer Agents
- Review, Var, NA
TumCG↓, angioG↓, Ferroptosis↑, TumCP↑, TumAuto↑, CSCs↑, eff↑, YAP/TEAD↓, TumCCA↑, ROS↑, ChemoSen↑, N-cadherin↓, Vim↓, MMP9↓, eff↑, STAT3↓, CD133↓, CD44↓, Nanog↓, cMyc↓, OCT4↓, Akt↓, mTOR↓,
5447- ATV,    The Mevalonate Pathway, a Metabolic Target in Cancer Therapy
- Review, Var, NA
Risk↓, Dose↑, ChemoSen↑, chemoP↑, HMG-CoA↓, EMT↓, CSCs↓, HH↝, YAP/TEAD↝,
5719- BF,    Bufalin inhibits the proliferation of lung cancer cells by suppressing Hippo-YAP pathway
- in-vitro, Lung, NA
TumCP↓, Hippo↓, YAP/TEAD↓,
741- Bor,    Boron Derivatives Inhibit the Proliferation of Breast Cancer Cells and Affect Tumor-Specific T Cell Activity In Vitro by Distinct Mechanisms
- in-vitro, BC, MCF7 - in-vitro, BC, MDA-MB-231
MOB1↓, PD-L1↑, p‑YAP/TEAD↝, IFN-γ↓, sFasL↑, Perforin↓, GranA↓, GranB/GZMB↓, GNLY↓, PD-1↑,
6642- Cen,    Asiaticoside inhibits breast cancer progression and tumor angiogenesis via YAP1/VEGFA signal pathway
- vitro+vivo, BC, MCF7 - in-vitro, BC, MDA-MB-231
TumCP↓, TumCI↓, angioG↓, TumCG↓, YAP/TEAD↓, VEGF↓, TumCCA↑,
7185- CHA,    Chaetocin-induced ROS-mediated apoptosis involves ATM–YAP1 axis and JNK-dependent inhibition of glucose metabolism
- vitro+vivo, GBM, A172 - in-vitro, GBM, T98G - in-vitro, GBM, U87MG
HMTs↓, ROS↑, p‑ATM↑, YAP/TEAD↑, p‑JNK↑, TumPF↓, SUV39H↓, TrxR↓, Casp3↑, Trx1↓, H3↓, lactateProd↓, ATP↓, GlucoseCon↓, TumCG↓, Dose↝,
7167- CHA,    Chaetocin-induced ROS-mediated apoptosis involves ATM-YAP1 axis and JNK-dependent inhibition of glucose metabolism
- vitro+vivo, GBM, A172 - in-vitro, GBM, T98G - in-vitro, GBM, U87MG
HMTs↓, ROS↑, YAP/TEAD↑, ATM↑, JNK↑, Apoptosis↑, GlucoseCon↓, lactateProd↓, ATP↓, TumCP↓, TrxR↓, Trx1↓, H3K9↓, p‑ATM↑, γH2AX↑, ALDOB↑, ENO3↑, FBP1↑, GSK‐3β↑, HK3↑, PCK1↑, PGK2↑, PGM1↑, PGM3↑, PHKG1↑, PKLR↑, HK2↓, PCNA↓,
6185- Cuc,    Cucurbitacin B: A review of its pharmacology, toxicity, and pharmacokinetics
- Review, Var, NA - Review, Arthritis, NA - Review, AD, NA
*Inflam↓, *antiOx↑, *hepatoP↑, *neuroP↑, *AntiCan↑, *toxicity↝, *BioAv↓, *HO-1↑, *NRF2↑, *NLRP3↑, *SOD↑, *SOD1↑, *ROS↓, *AntiAge↑, *ARE↑, *STAT↓, *NF-kB↓, *neuroG↑, *memory↑, ROS↑, NLRP3↑, CIP2A↓, Akt↓, STAT3↑, VEGFR2/KDR/Flk1↓, DNMTs↓, MAPK↓, YAP/TEAD↓, PI3K↓, Wnt↓, NOTCH↓, TumCCA↑, TumCG↓, TumCP↓, FAK↑, MMP9↓, TumAuto↑, toxicity↝, BioAv↓, Half-Life↝, BioAv↑, selectivity∅,
684- EGCG,    Improving the anti-tumor effect of EGCG in colorectal cancer cells by blocking EGCG-induced YAP activation
- in-vitro, CRC, NA
eff↑, Akt↓, VEGFR2/KDR/Flk1↓, STAT3↓, P53↓, Hippo↓, YAP/TEAD↑,
7467- HNK,    Honokiol regulates ovarian cancer cell malignant behavior through YAP/TAZ pathway modulation
- vitro+vivo, Oral, NA
tumCV↓, TumCP↓, TumCMig↓, TumCI↓, YAP/TEAD↓, TAZ↓, TumCG↓,
7458- HNK,    Honokiol induces ferroptosis in ovarian cancer cells through the regulation of YAP by OTUB2
- in-vitro, Ovarian, OVCAR-3
TumCP↓, TumCI↓, Ferroptosis↑, YAP/TEAD↓, OTUB2↓,
7663- IP,    Industrial additive and dietary fiber inulin induces tumor-selective necrotic death via mitochondrial lipid peroxidation involving MYC and YAP
GutMicro↑, lipid-P↑, mtDam↑, eff↑, Myc↓, YAP/TEAD↓, AR↑,
8032- IVM,    Tumor growth suppression of ivermectin in gastric cancer cell lines and primary gastric cancer organoids
- in-vitro, GC, SNU620 - in-vitro, GC, SNU719
tumCV↓, ChemoSen↑, tumCV∅, YAP/TEAD↓, Apoptosis↑,
8028- IVM,    Ivermectin as an Alternative Anticancer Agent: A Review of Its Chemical Properties and Therapeutic Potential
- Review, Var, NA
*BioAv↝, Apoptosis↑, TumCP↓, Wnt↓, β-catenin/ZEB1↓, TumCG↓, TumMeta↓, PI3K↓, Akt↓, mTOR↓, TumPF↓, CSCs↓, eff↑, ChemoSen↑, mtDam↑, MMP↓, ATP↓, ROS↑, NF-kB↓, BAX↑, Casp3↑, Casp9↑, ICD↑, Ki-67↓, PSA↓, YAP/TEAD↓,
8027- IVM,    Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin
- Review, Var, NA
*AntiP↑, TumCD↑, PAK1↑, TumAuto↑, Casp↑, ICD↑, TCF↝, Hippo↓, Akt↓, mTOR↓, angioG↓, CSCs↓, MMP↓, Cyt‑c↑, Apoptosis↑, BAX↑, P53↑, Bcl-2↓, cycE/CCNE↓, cycD1/CCND1↓, CDK2↓, CDK6↓, CDK4↓, YAP/TEAD↓, TFE3↑, mTORC1↓, mitResp↓, OCR↓, compI↓, MMP↓, ROS↑, SOD2↑, ATP↓, eff↓, mitA↓, P-gp/ABCB1↓, TumVol↓,
8023- IVM,    Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer
- vitro+vivo, GC, NA
YAP/TEAD↓, TumCG↓,
8040- IVM,    Ivermectin, a potential anticancer drug derived from an antiparasitic drug
- Review, Var, NA
Akt↓, mTOR↓, TumAuto↑, TumCP↓, TumCCA↑, Wnt↓, YAP/TEAD↓, MMP↓, mitResp↓, ATP↓, eff↓, eff↑, ROS↑, ChemoSen↑, PAK1↓, MAPK↓, EMT↓, Beclin-1↑, ATG5↑, CSCs↓, STAT3↝, P-gp/ABCB1↓, MDR1↓, HSP27↓, Chl↑, TFE3↑,
1125- LT,    Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity
- in-vitro, BC, NA
YAP/TEAD↓, TAZ↓, MSCmark↓, EM↑, TumCMig↓,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1/CCND1↓, CycB/CCNB1↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2/KDR/Flk1↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2/PTGS2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT/TERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
6419- MEL,    The potential influence of melatonin on mitochondrial quality control: a review
- Review, Nor, NA
*mt-ACC⇅, *PKM1↑, *PKM2↑, *Glycolysis↝, *PDKs↑, *FAO↑, *ETC↑, *OXPHOS↑, *ATP↑, Glycolysis↓, OXPHOS↑, *Ca+2↓, *ROS↓, *antiOx↑, *SOD2↑, *GPx↑, *Catalase↑, *MFN1↑, *MFN2↑, *OPA1↑, *YAP/TEAD↑, *Hippo↑, *SIRT1↑, *PGC-1α↑, *DRP1/DNM1L↓,
1042- MEL,    Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer
- in-vitro, Lung, A549 - in-vitro, Lung, H460 - in-vitro, Lung, LLC1
PD-L1↓, YAP/TEAD↓, TAZ↓, TumCG↓,
2247- MF,    Effects of Pulsed Electromagnetic Field Treatment on Skeletal Muscle Tissue Recovery in a Rat Model of Collagenase-Induced Tendinopathy: Results from a Proteome Analysis
- in-vivo, Nor, NA
*Glycolysis↓, *LDHB↑, *NAD↑, *ATP↑, *antiOx↑, *ROS↑, *YAP/TEAD↑, *PGC-1α↑, *TCA↑, *FAO↑, *OXPHOS↑,
5242- MFrot,    Rotating magnetic field downregulating type XI collagen to suppress triple-negative breast cancer metastasis by inactivating the ITGB1/FAK/YAP signaling pathway
- in-vitro, BC, NA
TumCI↓, COL11A1↓, TumCG↓, TumMeta↓, ITGB1↓, FAK↓, YAP/TEAD↓, Dose↝,
3083- RES,    Resveratrol suppresses breast cancer cell invasion by inactivating a RhoA/YAP signaling axis
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
YAP/TEAD↓, Rho↓, FAK↓, MMP9↓, ChemoSen↑, RAS↓, ROCK1↓, TumCI↓, TumMeta↓,
7375- RS,    Regulation of hippo signaling mediated apoptosis by Rauvolfia tetraphylla in triple-negative breast cancer
- in-vitro, BC, MDA-MB-231
eff↝, TumCCA↑, TumCMig↓, ROS↑, BAX↑, Mst1↑, Bcl-2↓, YAP/TEAD↓, LATS1↓,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31/PECAM-1↓, Hif1a↓, VEGFR2/KDR/Flk1↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
2234- SK,    Shikonin Suppresses Cell Tumorigenesis in Gastric Cancer Associated with the Inhibition of c-Myc and Yap-1
- in-vitro, GC, NA
TumCP↓, TumCI↓, TumCMig↓, cMyc↓, YAP/TEAD↓,
3107- VitC,    Repurposing Vitamin C for Cancer Treatment: Focus on Targeting the Tumor Microenvironment
- Review, Var, NA
Risk↓, *ROS↓, ROS↑, VEGF↓, COX2/PTGS2↓, ER Stress↑, IRE1↑, JNK↑, CHOP/DDIT3↑, Hif1a↓, eff↑, Glycolysis↓, MMPs↓, TumMeta↓, YAP/TEAD↓, eff↑, TET1↑,
1751- WBV,    Yoda1 Enhanced Low-Magnitude High-Frequency Vibration on Osteocytes in Regulation of MDA-MB-231 Breast Cancer Cell Migration
- in-vitro, BC, MDA-MB-231 - in-vitro, AML, RAW264.7
BMD↑, YAP/TEAD↑, TumCG↓, Strength↑, TumCI↓, Fas↑, Ca+2↑,

Showing Research Papers: 1 to 30 of 30

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 30

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

ALDOB↑, 1,   CCN1/CYR61↓, 1,   ENO3↑, 1,   H3K9↓, 1,   HK3↑, 1,   LATS1↓, 1,   OTUB2↓, 1,   PGK2↑, 1,   PGM3↑, 1,   PHKG1↑, 1,   PKLR↑, 1,   SUV39H↓, 1,   TFE3↑, 2,  

Redox & Oxidative Stress(tgid=1) ⓘ

compI↓, 1,   Ferroptosis↑, 2,   GSH↑, 1,   HO-1↓, 1,   ICD↑, 2,   lipid-P↓, 1,   lipid-P↑, 1,   NRF2↓, 1,   NRF2↑, 1,   OXPHOS↑, 1,   ROS↑, 10,   SIRT3↓, 1,   SOD2↑, 1,   Trx1↓, 2,   TrxR↓, 2,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 5,   CDC2↓, 1,   MEK↓, 1,   mitResp↓, 2,   MMP↓, 6,   mtDam↑, 2,   OCR↓, 1,   Raf↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 3,   p‑cMyc↑, 1,   FBP1↑, 1,   GlucoseCon↓, 2,   Glycolysis↓, 2,   HK2↓, 1,   HMG-CoA↓, 1,   lactateProd↓, 2,   PCK1↑, 1,   PGM1↑, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 9,   APAF1↑, 1,   Apoptosis↑, 4,   BAX↑, 6,   Bcl-2↓, 4,   Bcl-xL↓, 1,   BIM↓, 1,   Casp↓, 1,   Casp↑, 2,   Casp3↑, 3,   cl‑Casp3↑, 1,   cl‑Casp8↑, 1,   Casp9↑, 1,   cl‑Casp9↑, 1,   Cyt‑c↑, 2,   DR5↑, 1,   Fas↑, 1,   Ferroptosis↑, 2,   GranA↓, 1,   GranB/GZMB↓, 1,   Hippo↓, 3,   hTERT/TERT↓, 1,   iNOS↓, 1,   JNK↑, 3,   p‑JNK↑, 1,   MAPK↓, 4,   MDM2↓, 1,   Myc↓, 1,   NICD↓, 1,   Perforin↓, 1,   sFasL↑, 1,   survivin↓, 2,   Telomerase↓, 1,   TumCD↑, 1,   YAP/TEAD↓, 22,   YAP/TEAD↑, 4,   YAP/TEAD↝, 1,   p‑YAP/TEAD↝, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

H3↓, 1,   HATs↑, 1,   tumCV↓, 2,   tumCV∅, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   ER Stress↑, 2,   HSP27↓, 1,   IRE1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   Beclin-1↑, 1,   LC3B-II↑, 1,   LC3II↑, 1,   TumAuto↑, 5,  

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1,   p‑ATM↑, 2,   DNAdam↑, 1,   DNMT1↓, 1,   DNMTs↓, 1,   P53↓, 1,   P53↑, 4,   cl‑PARP↑, 1,   PCNA↓, 3,   SIRT6↓, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 2,   CDK4↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 4,   cycE/CCNE↓, 1,   mitA↓, 1,   P21↑, 1,   TumCCA↑, 6,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD133↓, 2,   CD44↓, 1,   CIP2A↓, 1,   CSCs↓, 5,   CSCs↑, 1,   EMT↓, 4,   ERK↓, 2,   GSK‐3β↑, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 1,   HH↝, 1,   HMTs↓, 2,   miR-34a↑, 1,   MSCmark↓, 1,   Mst1↑, 1,   mTOR↓, 5,   mTORC1↓, 1,   Nanog↓, 2,   NOTCH↓, 1,   NOTCH1↓, 1,   OCT4↓, 1,   PI3K↓, 5,   RAS↓, 2,   SOX2↓, 1,   STAT3↓, 2,   STAT3↑, 1,   STAT3↝, 1,   TAZ↓, 4,   TCF↝, 1,   TumCG↓, 10,   Wnt↓, 5,  

Migration(tgid=13) ⓘ

AEG1↓, 1,   Ca+2↑, 2,   CCN2/CTGF↓, 1,   CD31/PECAM-1↓, 1,   Chl↑, 1,   COL11A1↓, 1,   E-cadherin↑, 1,   EM↑, 1,   FAK↓, 2,   FAK↑, 1,   ITGB1↓, 1,   Ki-67↓, 1,   MMP2↓, 1,   MMP9↓, 5,   MMPs↓, 2,   MOB1↓, 1,   N-cadherin↓, 2,   PAK1↓, 1,   PAK1↑, 1,   Rho↓, 1,   ROCK1↓, 1,   TET1↑, 1,   TGF-β↓, 1,   TIMP1↑, 1,   TIMP2↑, 1,   TumCI↓, 7,   TumCMig↓, 5,   TumCP↓, 11,   TumCP↑, 1,   TumMeta↓, 6,   TumPF↓, 2,   uPA↓, 1,   Vim↓, 1,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 5,   Hif1a↓, 2,   VEGF↓, 5,   VEGFR2/KDR/Flk1↓, 4,  

Barriers & Transport(tgid=15) ⓘ

P-gp/ABCB1↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 3,   CXCR4↓, 1,   GNLY↓, 1,   IFN-γ↓, 2,   IFN-γ↑, 1,   IL10↓, 1,   IL2↑, 1,   IL6↓, 1,   Inflam↓, 2,   MDSCs↓, 1,   NF-kB↓, 3,   p‑NF-kB↑, 1,   PD-1↑, 1,   PD-L1↓, 1,   PD-L1↑, 1,   PSA↓, 1,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,   AR↑, 1,   CDK6↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 1,   ChemoSen↓, 1,   ChemoSen↑, 8,   Dose↑, 1,   Dose↝, 2,   eff↓, 2,   eff↑, 8,   eff↝, 1,   Half-Life↝, 1,   MDR1↓, 2,   RadioS↑, 1,   selectivity∅, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   AR↑, 1,   BMD↑, 1,   GutMicro↑, 1,   hTERT/TERT↓, 1,   IL6↓, 1,   Ki-67↓, 1,   Myc↓, 1,   PD-L1↓, 1,   PD-L1↑, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

cardioP↑, 1,   chemoP↑, 2,   hepatoP↑, 1,   neuroP↑, 1,   Risk↓, 2,   Strength↑, 1,   toxicity↝, 1,   TumVol↓, 1,  
Total Targets: 238

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiP↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 4,   ARE↑, 1,   Catalase↑, 1,   GPx↑, 1,   HO-1↑, 1,   MFN1↑, 1,   MFN2↑, 1,   NRF2↑, 1,   OPA1↑, 1,   OXPHOS↑, 2,   ROS↓, 3,   ROS↑, 1,   SOD↑, 1,   SOD1↑, 1,   SOD2↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↑, 2,   DRP1/DNM1L↓, 1,   ETC↑, 1,   PGC-1α↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

mt-ACC⇅, 1,   FAO↑, 2,   Glycolysis↓, 1,   Glycolysis↝, 1,   LDHB↑, 1,   NAD↑, 1,   PDKs↑, 1,   PKM1↑, 1,   PKM2↑, 1,   SIRT1↑, 1,   TCA↑, 1,  

Cell Death(tgid=5) ⓘ

Hippo↑, 1,   YAP/TEAD↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

neuroG↑, 1,   STAT↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,   NF-kB↓, 1,  

Protein Aggregation(tgid=19) ⓘ

NLRP3↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↑, 1,   BioAv↝, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   AntiCan↑, 1,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 1,   toxicity↓, 1,   toxicity↝, 1,  
Total Targets: 50

Scientific Paper Hit Count for: YAP/TEAD, YAP/TEAD activity
5 Ivermectin
2 chaetocin
2 Honokiol
2 Luteolin
2 Melatonin
1 Apigenin (mainly Parsley)
1 Isovitexin
1 Artemisinin
1 Atorvastatin
1 Bufalin/Huachansu
1 Boron
1 Centella asiatica / Gotu kola → asiaticoside
1 Cucurbitacin
1 EGCG (Epigallocatechin Gallate)
1 Inulin Prebiotic
1 Magnetic Fields
1 Magnetic Field Rotating
1 Resveratrol
1 Rauwolfia serpentina/Indian Snakeroot
1 Silymarin (Milk Thistle) silibinin
1 Shikonin
1 Vitamin C (Ascorbic Acid)
1 Whole Body Vibration
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:340  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page